New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
09:22 EDTSTJSt. Jude Medical warning letter not clearing event, says Citigroup
Citigroup believes the next FDA action regarding St. Jude Medical's Sylmar is likely to be a threat of injunction that normally leads to a consent decree. Further, Citi believes the FDA will ultimately have to make a determination on the safety of Durata, with the firm still believing a recall is likely. Citi says the FDA's Sylmar Warning Letter is not a clearing event, but the next step in a process that looks ominous for St. Jude. The firm keeps a Sell rating on the stock with a $32 price target.
News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:34 EDTSTJEnteroMedics names Brad Hancock Chief Commercial Officer
Subscribe for More Information
October 27, 2014
08:04 EDTSTJSt. Jude Medical receives FDA approval of Tacticath Quartz catheter
Subscribe for More Information
October 22, 2014
07:21 EDTSTJU.S. DHS investigates medical gear for potential cyber defects, Reuters says
Subscribe for More Information
October 20, 2014
07:12 EDTSTJCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use